Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Curvebeam AI Ltd. ( (AU:CVB) ).
CurveBeam AI Limited announced the completion of its $6.5 million placement with the receipt of the remaining $900,000, leading to the issuance of 10,000,000 fully paid ordinary shares at $0.09 per share. This strategic financial move, conducted under ASX Listing Rules 7.1 and 7.1A, strengthens the company’s financial position and supports its ongoing operations in the medical imaging industry. The announcement signifies compliance with relevant provisions of the Corporations Act and assures stakeholders of the company’s adherence to regulatory standards.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a company that develops, manufactures, and sells specialized medical imaging CT scanners, along with AI SaaS-based clinical assessment solutions. These products are designed to assist medical practitioners in managing musculoskeletal conditions. The company’s flagship product, the HiRise™ CT scanner, offers both weight-bearing and traditional non-weight-bearing CT scans, providing advantages over traditional CT or MRI devices. CurveBeam AI operates with over 70 employees, with its corporate office and AI functions based in Melbourne, Australia, and its global operations headquarters in Hatfield, Pennsylvania, USA.
Average Trading Volume: 357,165
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$43.5M
Learn more about CVB stock on TipRanks’ Stock Analysis page.